http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2111868-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f11390a0601d6520c1d8695c6a4f6744 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-38 |
| filingDate | 2008-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d087e9bf6ce118a52707013ce5891f5f |
| publicationDate | 2009-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2111868-A1 |
| titleOfInvention | Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders |
| abstract | Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders. n The invention is based on the use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders, in which the model of administration of the drug comprises the administration to the patient for a minimum of three successive times of a therapeutically effective amount of human therapeutic albumin by plasma exchange and/or intravenous perfusion, independently of the content of Aβ in the patient's blood. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10357513-B2 |
| priorityDate | 2007-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.